Estradiol transdermal micro patch - Noven Pharmaceuticals

Drug Profile

Estradiol transdermal micro patch - Noven Pharmaceuticals

Alternative Names: Estradot; Minivelle; Vivelle-Dot

Latest Information Update: 20 Apr 2017

Price : $50

At a glance

  • Originator Noven Pharmaceuticals
  • Developer Novartis; Noven Pharmaceuticals
  • Class Antineoplastics; Estradiol congeners; Estrenes; Hormonal replacements; Small molecules
  • Mechanism of Action Estrogen receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Atrophic vaginitis; Menopausal syndrome; Postmenopausal osteoporosis; Primary ovarian insufficiency; Vasomotor symptoms

Most Recent Events

  • 05 May 2015 Noven Pharmaceuticals and Hisamitsu Pharmaceutical filed first-to-file patent-challenge lawsuit relating to the generic version of Minivelle® in the US against Mylan N.V. and its subsidiaries
  • 18 Feb 2015 Launched for Postmenopausal osteoporosis (Prevention) in the US (Transdermal, Minivelle® 0.025 mg/day)
  • 22 Dec 2014 First generic equivalent launched in USA for Postmenopausal osteoporosis (Prevention) and Menopausal syndrome
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top